INHIBITORS OF NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDE (HSEP) FOR PROFILAXIS AND TREATMENT OF NEUROGENERATIVE DISORDERS.

摘要

Use of a compound of general formula (1) (See formula) where R1 represents a group of formula (2) or (3): (See formulas) A represents CH2, O or S, R2 and R3 independently represent hydrogen or halogen, R4 and R6 independently represent hydrogen or a group that forms a bi-volatile carboxylic ester; R5 is selected from the group consisting of (C1-C6) alkoxy (C1-C6) alkyl which may be substituted by (C1-C6) alkoxy, phenyl-C1-C6 alkyl and phenyloxy-C1-C6 alkyl where the phenyl group may be substituted with (C1-C6) alkyl, (C1-C6) alkoxy or halogen, and naphthyl (C1-C6) alkyl, R7 and R8 independently represent hydrogen or a group that forms a bi-labile phosphonic acid ester , all stereoisomers, as well as pharmacologically acceptable salts thereof, for the preparation of pharmaceutical compositions for the prophylaxis and treatment of conditions selected from the group consisting of traumatic brain injury, disseminated acute encephalomyelitis, epilepsy-related brain injury, spinal cord, meningitis and bacterial or viral meningoencephalitis, prion diseases, poisoning with neurotoxic compounds, radiation-induced brain injury and for ischemic stroke prophylaxis, with the condition that That such pharmaceutical compositions do not contain an aldosterone receptor antagonist.